David Brindley MENG, DPHIL, FRI, FRSA

Dr. David is an international thought-leader in the translation of life-science innovations into commercially viable products and services. His expertise spans the ‘Valley of Death,’ encompassing regulation, engineering and finance. This distinctive skill set positions David at the forefront of healthcare translation.

Currently David’s professional activities include: research into the optimization of risk: benefit appraisal techniques for healthcare innovations, leading the CASMI Translational Stem Cell Consortium and providing timely and pragmatic advice to a range of stakeholders in healthcare translation, notably the venture capital community.

Examples of David’s work can be found in a range of high impact journals including Nature, Nature Biotechnology, Nature Medicine and Cell Stem Cell. Keen to leverage novel media channels, David also produces a popular blog, Cell Therapy Industry 2027.

Outside the academia, David is an active Fellow of the Royal Institution of Great Britain and the Royal Society for the Advancement of Arts and Manufacturing. David has successfully passed the Charted Analyst in Alternative Investments (CAIA) Level 1 examination.

David completed his undergraduate studies in Biochemical Engineering at University College London with First Class Honours (Prof. Chris Mason and Dr Ivan Wall) and his Masters, jointly at the Harvard Stem Cell Institute (Mr Brock Reeve) and Harvard Business School (Prof. William Sahlman). Today, in addition to remaining an active member of the Harvard Stem Cell Institute and University College London (Behavioral Medicine), David completed his DPhil (PhD) in Musculoskeletal Sciences at the University of Oxford (Prof. Andrew Carr FMedSci and Prof. Sir John Bell FRS FMedSci).

Beyond life science translation, David is an aggressive tennis player, impactful rower, passionate skier, passable glider pilot, aspiring sailor – and a lover of all things travel and epicurean!